Education and Training
- M.D., University of Texas, Medical Branch at Galveston, 1995
In the News
- Duke University unveils airport safety researchNovember 7, 2013
Lin, Katherine A., Kingshuk Roy Choudhury, Bharath G. Rathakrishnan, David M. Marks, Jeffrey R. Petrella, P Murali Doraiswamy, and P Murali Alzheimer’s Disease Neuroimaging Initiative. “Marked gender differences in progression of mild cognitive impairment over 8 years.” Alzheimers Dement (N Y) 1, no. 2 (September 1, 2015): 103–10. https://doi.org/10.1016/j.trci.2015.07.001.
Marks, David M., and Amy Newhouse. “Durability of Benefit From Repeated Intravenous Lidocaine Infusions in Fibromyalgia Patients: A Case Series and Literature Review.” Prim Care Companion Cns Disord 17, no. 5 (2015). https://doi.org/10.4088/PCC.15br01804.
Marks, David M., Chi-Un Pae, and Ashwin A. Patkar. “A double-blind, placebo-controlled, parallel-group pilot study of milnacipran for chronic radicular pain (sciatica) associated with lumbosacral disc disease.” Prim Care Companion Cns Disord 16, no. 4 (2014). https://doi.org/10.4088/PCC.14m01658.
Kim, Jeong Lan, Shilpa Rele, David M. Marks, Prakash S. Masand, Pallavi Yerramsetty, Robert A. Millet, Richard S. Keefe, and Ashwin A. Patkar. “Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial.” Prim Care Companion Cns Disord 15, no. 6 (2013). https://doi.org/10.4088/PCC.13m01555.
Marks, David M., and Michael P. Bolognesi. “Open-label milnacipran for patients with persistent knee pain 1 year or longer after total knee arthroplasty: a pilot study.” Prim Care Companion Cns Disord 15, no. 4 (2013). https://doi.org/10.4088/PCC.12m01496.
Marks, David M., Jonathan S. Abramowitz, and Glen I. Spielmans. “Concerns about data reporting and interpretation in "Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial".” J Psychiatr Res 46, no. 5 (May 2012): 692–93. https://doi.org/10.1016/j.jpsychires.2012.02.002.
Marks, D. M. “Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression.” Drugs of the Future 37, no. 4 (April 1, 2012): 241–46. https://doi.org/10.1358/dof.2012.37.4.1782933.
Marks, D. M. “Amitifadine hydrochloride: Triple reuptake inhibitor treatment of depression.” Drugs of the Future 37, no. 4 (January 1, 2012): 241–46. https://doi.org/10.1358/dof.2012.037.04.1782933.
Hardy, T. A., R. R. Henry, T. D. Forrester, L. A. Kryzhanovskaya, G. M. Campbell, D. M. Marks, and S. Mudaliar. “Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.” Diabetes Obes Metab 13, no. 8 (August 2011): 726–35. https://doi.org/10.1111/j.1463-1326.2011.01398.x.
Pae, Chi-Un, Haresh Tharwani, David M. Marks, Prakash S. Masand, and Ashwin A. Patkar. “Atypical depression: a comprehensive review.” Cns Drugs 23, no. 12 (December 2009): 1023–37. https://doi.org/10.2165/11310990-000000000-00000.